Brief: VistaGen Announces Positive Results From Phase 2A Pilot Study Of PH15

Vistagen Therapeutics

25/04/2024 14:21

April 25 (Reuters) - VistaGen Therapeutics Inc  VTGN.O :
    * VISTAGEN ANNOUNCES POSITIVE RESULTS FROM PHASE 2A PILOT
STUDY OF
PH15 FOR IMPROVEMENT OF PSYCHOMOTOR IMPAIRMENT CAUSED BY MENTAL
FATIGUE
    * VISTAGEN THERAPEUTICS INC: PH15 NASAL SPRAY DEMONSTRATES
STATISTICALLY SIGNIFICANT EFFICACY VERSUS PLACEBO AND CAFFEINE
    * VISTAGEN THERAPEUTICS INC: PH15 WAS SAFE AND
WELL-TOLERATED WITH
AN ADVERSE EVENT PROFILE SIMILAR TO PLACEBO

Source text for Eikon:  ID:nBw4KZVDta 
Further company coverage:  VTGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))